APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Central Nervous System (CNS) Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Central Nervous System (CNS) Therapeutics Market Analysis and Forecast 2026-2032

29 December 2025199 pages

Choose your research edition.

Industry ResearchCentral Nervous System (CNS) Therapeutics Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Central Nervous System (CNS) Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Central Nervous System (CNS) Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Central Nervous System (CNS) Therapeutics Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Central Nervous System (CNS) Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Central Nervous System (CNS) Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Central Nervous System (CNS) Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Central Nervous System (CNS) Therapeutics include Biogen, UCB Pharma, Viatris, Eli Lilly, Roche, Merck & Co Inc, Novartis, Johnson and Johnson and Teva, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Central Nervous System (CNS) Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Central Nervous System (CNS) Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Central Nervous System (CNS) Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Central Nervous System (CNS) Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Central Nervous System (CNS) Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Central Nervous System (CNS) Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Central Nervous System (CNS) Therapeutics Segment by Company

Biogen

UCB Pharma

Viatris

Eli Lilly

Roche

Merck & Co Inc

Novartis

Johnson and Johnson

Teva

Takeda

Central Nervous System (CNS) Therapeutics Segment by Type

CNS Trauma

Neurovascular Diseases

Neurodegenerative Diseases

Other

Central Nervous System (CNS) Therapeutics Segment by Application

Hospital

Online

Other

Central Nervous System (CNS) Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Central Nervous System (CNS) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Central Nervous System (CNS) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Central Nervous System (CNS) Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Central Nervous System (CNS) Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Central Nervous System (CNS) Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Central Nervous System (CNS) Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CNS Trauma Major Player Table 3. Neurovascular Diseases Major Player Table 4. Neurodegenerative Diseases Major Player Table 5. Other Major Player Table 6. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Hospital Major Player Table 8. Online Major Player Table 9. Other Major Player Table 10. Central Nervous System (CNS) Therapeutics Industry Trends Table 11. Central Nervous System (CNS) Therapeutics Industry Drivers Table 12. Central Nervous System (CNS) Therapeutics Industry Opportunities and Challenges Table 13. Central Nervous System (CNS) Therapeutics Industry Restraints Table 14. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Central Nervous System (CNS) Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Central Nervous System (CNS) Therapeutics Market Share by Region (2021-2026) Table 17. Global Central Nervous System (CNS) Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Central Nervous System (CNS) Therapeutics Market Share by Region (2027-2032) Table 19. Global Central Nervous System (CNS) Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Players (2021-2026) Table 21. Global Central Nervous System (CNS) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Central Nervous System (CNS) Therapeutics Key Players Headquarters & Area Served Table 23. Global Central Nervous System (CNS) Therapeutics Players, Product Type & Application Table 24. Global Central Nervous System (CNS) Therapeutics Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Central Nervous System (CNS) Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Central Nervous System (CNS) Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Type (2021-2026) Table 31. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Type (2027-2032) Table 32. Global Central Nervous System (CNS) Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2021-2026) Table 36. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2027-2032) Table 37. Biogen Company Information Table 38. Biogen Business Overview Table 39. Biogen Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Biogen Central Nervous System (CNS) Therapeutics Product Portfolio Table 41. Biogen Recent Development Table 42. UCB Pharma Company Information Table 43. UCB Pharma Business Overview Table 44. UCB Pharma Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio Table 46. UCB Pharma Recent Development Table 47. Viatris Company Information Table 48. Viatris Business Overview Table 49. Viatris Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Viatris Central Nervous System (CNS) Therapeutics Product Portfolio Table 51. Viatris Recent Development Table 52. Eli Lilly Company Information Table 53. Eli Lilly Business Overview Table 54. Eli Lilly Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio Table 56. Eli Lilly Recent Development Table 57. Roche Company Information Table 58. Roche Business Overview Table 59. Roche Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Roche Central Nervous System (CNS) Therapeutics Product Portfolio Table 61. Roche Recent Development Table 62. Merck & Co Inc Company Information Table 63. Merck & Co Inc Business Overview Table 64. Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio Table 66. Merck & Co Inc Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Novartis Central Nervous System (CNS) Therapeutics Product Portfolio Table 71. Novartis Recent Development Table 72. Johnson and Johnson Company Information Table 73. Johnson and Johnson Business Overview Table 74. Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio Table 76. Johnson and Johnson Recent Development Table 77. Teva Company Information Table 78. Teva Business Overview Table 79. Teva Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Teva Central Nervous System (CNS) Therapeutics Product Portfolio Table 81. Teva Recent Development Table 82. Takeda Company Information Table 83. Takeda Business Overview Table 84. Takeda Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Takeda Central Nervous System (CNS) Therapeutics Product Portfolio Table 86. Takeda Recent Development Table 87. North America Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 88. North America Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 89. North America Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 90. North America Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 91. North America Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 92. North America Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 93. North America Central Nervous System (CNS) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 94. Europe Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 95. Europe Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 96. Europe Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 97. Europe Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 98. Europe Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Europe Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 100. Europe Central Nervous System (CNS) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 101. China Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 102. China Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 103. China Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 104. China Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 105. Asia Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 106. Asia Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 107. Asia Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 108. Asia Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 109. Asia Central Nervous System (CNS) Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Asia Central Nervous System (CNS) Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 111. Asia Central Nervous System (CNS) Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 112. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 113. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 114. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 115. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 116. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 117. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 118. SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 119. Research Programs/Design for This Report Table 120. Authors List of This Report Table 121. Secondary Sources Table 122. Primary Sources List of Figures Figure 1. Central Nervous System (CNS) Therapeutics Image Figure 2. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Central Nervous System (CNS) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. CNS Trauma Image Figure 5. Neurovascular Diseases Image Figure 6. Neurodegenerative Diseases Image Figure 7. Other Image Figure 8. Global Central Nervous System (CNS) Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Central Nervous System (CNS) Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 10. Hospital Image Figure 11. Online Image Figure 12. Other Image Figure 13. Global Central Nervous System (CNS) Therapeutics Market Size (US$ Million) & (2021-2032) Figure 14. Global Central Nervous System (CNS) Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Central Nervous System (CNS) Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Central Nervous System (CNS) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Central Nervous System (CNS) Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Central Nervous System (CNS) Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Type (2021-2032) Figure 21. Global Central Nervous System (CNS) Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2021-2032) Figure 24. North America Central Nervous System (CNS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032) Figure 26. North America Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032) Figure 27. North America Central Nervous System (CNS) Therapeutics Revenue Share by Country (2021-2032) Figure 28. United States Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Central Nervous System (CNS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032) Figure 33. Europe Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032) Figure 34. Europe Central Nervous System (CNS) Therapeutics Revenue Share by Country (2021-2032) Figure 35. Germany Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Central Nervous System (CNS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032) Figure 45. China Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032) Figure 46. Asia Central Nervous System (CNS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032) Figure 48. Asia Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032) Figure 49. Asia Central Nervous System (CNS) Therapeutics Revenue Share by Region (2021-2032) Figure 50. Japan Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Central Nervous System (CNS) Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032) Figure 58. SAMEA Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032) Figure 59. SAMEA Central Nervous System (CNS) Therapeutics Revenue Share by Country (2021-2032) Figure 60. Brazil Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Central Nervous System (CNS) Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • CNS Trauma
  • Neurovascular Diseases
  • Neurodegenerative Diseases
  • Other
Applications
  • Hospital
  • Online
  • Other
Companies covered
  • Biogen
  • UCB Pharma
  • Viatris
  • Eli Lilly
  • Roche
  • Merck & Co Inc
  • Novartis
  • Johnson and Johnson
  • Teva
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Central Nervous System (CNS) Therapeutics Market by Type
  3. 1.2.1 Global Central Nervous System (CNS) Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CNS Trauma
  5. 1.2.3 Neurovascular Diseases
  6. 1.2.4 Neurodegenerative Diseases
  7. 1.2.5 Other
  8. 1.3 Central Nervous System (CNS) Therapeutics Market by Application
  9. 1.3.1 Global Central Nervous System (CNS) Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Hospital
  11. 1.3.3 Online
  12. 1.3.4 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Central Nervous System (CNS) Therapeutics Market Dynamics
  1. 2.1 Central Nervous System (CNS) Therapeutics Industry Trends
  2. 2.2 Central Nervous System (CNS) Therapeutics Industry Drivers
  3. 2.3 Central Nervous System (CNS) Therapeutics Industry Opportunities and Challenges
  4. 2.4 Central Nervous System (CNS) Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Central Nervous System (CNS) Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Central Nervous System (CNS) Therapeutics Growth Trends by Region
  3. 3.2.1 Global Central Nervous System (CNS) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Central Nervous System (CNS) Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Central Nervous System (CNS) Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Central Nervous System (CNS) Therapeutics Revenue by Players
  2. 4.1.1 Global Central Nervous System (CNS) Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Central Nervous System (CNS) Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Central Nervous System (CNS) Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Central Nervous System (CNS) Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Central Nervous System (CNS) Therapeutics Players, Product Type & Application
  8. 4.5 Global Central Nervous System (CNS) Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Central Nervous System (CNS) Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Central Nervous System (CNS) Therapeutics Tier 1, Tier 2, and Tier 3
5 Central Nervous System (CNS) Therapeutics Market Size by Type
  1. 5.1 Global Central Nervous System (CNS) Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Type (2021-2032)
6 Central Nervous System (CNS) Therapeutics Market Size by Application
  1. 6.1 Global Central Nervous System (CNS) Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Central Nervous System (CNS) Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Biogen
  2. 7.1.1 Biogen Company Information
  3. 7.1.2 Biogen Business Overview
  4. 7.1.3 Biogen Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Biogen Central Nervous System (CNS) Therapeutics Product Portfolio
  6. 7.1.5 Biogen Recent Developments
  7. 7.2 UCB Pharma
  8. 7.2.1 UCB Pharma Company Information
  9. 7.2.2 UCB Pharma Business Overview
  10. 7.2.3 UCB Pharma Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 UCB Pharma Central Nervous System (CNS) Therapeutics Product Portfolio
  12. 7.2.5 UCB Pharma Recent Developments
  13. 7.3 Viatris
  14. 7.3.1 Viatris Company Information
  15. 7.3.2 Viatris Business Overview
  16. 7.3.3 Viatris Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Viatris Central Nervous System (CNS) Therapeutics Product Portfolio
  18. 7.3.5 Viatris Recent Developments
  19. 7.4 Eli Lilly
  20. 7.4.1 Eli Lilly Company Information
  21. 7.4.2 Eli Lilly Business Overview
  22. 7.4.3 Eli Lilly Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Eli Lilly Central Nervous System (CNS) Therapeutics Product Portfolio
  24. 7.4.5 Eli Lilly Recent Developments
  25. 7.5 Roche
  26. 7.5.1 Roche Company Information
  27. 7.5.2 Roche Business Overview
  28. 7.5.3 Roche Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Roche Central Nervous System (CNS) Therapeutics Product Portfolio
  30. 7.5.5 Roche Recent Developments
  31. 7.6 Merck & Co Inc
  32. 7.6.1 Merck & Co Inc Company Information
  33. 7.6.2 Merck & Co Inc Business Overview
  34. 7.6.3 Merck & Co Inc Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Merck & Co Inc Central Nervous System (CNS) Therapeutics Product Portfolio
  36. 7.6.5 Merck & Co Inc Recent Developments
  37. 7.7 Novartis
  38. 7.7.1 Novartis Company Information
  39. 7.7.2 Novartis Business Overview
  40. 7.7.3 Novartis Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Novartis Central Nervous System (CNS) Therapeutics Product Portfolio
  42. 7.7.5 Novartis Recent Developments
  43. 7.8 Johnson and Johnson
  44. 7.8.1 Johnson and Johnson Company Information
  45. 7.8.2 Johnson and Johnson Business Overview
  46. 7.8.3 Johnson and Johnson Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Johnson and Johnson Central Nervous System (CNS) Therapeutics Product Portfolio
  48. 7.8.5 Johnson and Johnson Recent Developments
  49. 7.9 Teva
  50. 7.9.1 Teva Company Information
  51. 7.9.2 Teva Business Overview
  52. 7.9.3 Teva Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Teva Central Nervous System (CNS) Therapeutics Product Portfolio
  54. 7.9.5 Teva Recent Developments
  55. 7.10 Takeda
  56. 7.10.1 Takeda Company Information
  57. 7.10.2 Takeda Business Overview
  58. 7.10.3 Takeda Central Nervous System (CNS) Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Takeda Central Nervous System (CNS) Therapeutics Product Portfolio
  60. 7.10.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Central Nervous System (CNS) Therapeutics Revenue (2021-2032)
  2. 8.2 North America Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Central Nervous System (CNS) Therapeutics Revenue by Country
  11. 8.6.1 North America Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Central Nervous System (CNS) Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Central Nervous System (CNS) Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Central Nervous System (CNS) Therapeutics Revenue by Country
  11. 9.6.1 Europe Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Central Nervous System (CNS) Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Central Nervous System (CNS) Therapeutics Revenue (2021-2032)
  2. 10.2 China Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Central Nervous System (CNS) Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Central Nervous System (CNS) Therapeutics Revenue by Country
  11. 11.6.1 Asia Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Central Nervous System (CNS) Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Central Nervous System (CNS) Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Central Nervous System (CNS) Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Central Nervous System (CNS) Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Central Nervous System (CNS) Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst